https://rheumatologydigest.org/tags/il-6-inhibitors/Recent content in Il-6-Inhibitors on Rheumatology DigestHugoen-usFri, 03 Jul 2026 05:00:00 +0530https://rheumatologydigest.org/posts/gca-pmr-beyond-glucocorticoids/Fri, 03 Jul 2026 05:00:00 +0530https://rheumatologydigest.org/posts/gca-pmr-beyond-glucocorticoids/A 2026 review of steroid-sparing therapy across the GCA–PMR spectrum: glucocorticoids still induce remission but drive substantial cumulative toxicity, so the field has pivoted to IL-6 receptor inhibition (tocilizumab in GCA, sarilumab in PMR) and JAK inhibition (upadacitinib now approved for GCA) — none of which reliably restores treatment-free remission, against a backdrop of weak monitoring tools and GCA-specific vascular-damage risk.